Thromboxane synthase inhibitors vs placebo
Adverse events · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
7 questions · 7 findings · 1 reviews · Vascular
No studies found 1 · 14.3%GRADE not reported 3 · 42.9%Very low 1 · 14.3%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Phosphodiesterase inhibitors vs placebo
Adverse events · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted3 studies · 138 participantsGRADE not reported
Prostagladin/prostacyclin analogues vs placebo
Adverse events (6 weeks' · primary Raynaud's phenomenon
Prostagladin/prostacyclin analogues may leads to higher adverse events (6 weeks' compared with placebo (low certainty).
1 finding from 1 review
- RR 1.59 [1.05, 2.42]1 study · 125 participantsLow
Nitrate/nitrate derivatives vs placebo
Adverse events (3 weeks' · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 8 participantsGRADE not reported
Angiotensin‐converting enzyme inhibitors vs placebo
Adverse events (4 to 6‐week · primary Raynaud's phenomenon
Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).
1 finding from 1 review
- RR 1.35 [0.67, 2.73]3 studies · 46 participantsLow
Selective serotonin reuptake inhibitors vs placebo
Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon
It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.54 [0.89, 2.66]1 study · 41 participantsVery low
Alpha‐blockers vs placebo
Adverse events (4 weeks' to 180 days' · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 33 participantsGRADE not reported